Association of 63/91 length polymorphism in the

Our aim was to explore the influence of 9-bp insertion/deletion and variable number of 9 bp elements ( ) length polymorphism in noncoding interfering RNA and major promoter of gene on methotrexate (MTX) efficacy and toxicity in patients with rheumatoid arthritis (RA). Response to the MTX therapy and...

Full description

Saved in:
Bibliographic Details
Published inPharmacogenomics Vol. 17; no. 15; pp. 1687 - 1691
Main Authors Jekic, Biljana, Vejnovic, Dubravka, Milic, Vera, Maksimovic, Nela, Damnjanovic, Tatjana, Bunjevacki, Vera, Novakovic, Ivana, Lukovic, Ljiljana, Damjanov, Nemanja, Krajinovic, Maja
Format Journal Article
LanguageEnglish
Published Future Medicine Ltd 01.10.2016
Subjects
dihydrofolate reductase
interfering RNA
methotrexate
polymorphism
rheumatoid arthritis
Online AccessGet full text

Cover

More Information
Summary:Our aim was to explore the influence of 9-bp insertion/deletion and variable number of 9 bp elements ( ) length polymorphism in noncoding interfering RNA and major promoter of gene on methotrexate (MTX) efficacy and toxicity in patients with rheumatoid arthritis (RA). Response to the MTX therapy and adverse effects were estimated in 243 RA patients genotyped for the selected polymorphism. The presence of allele 1 of analyzed polymorphism had significant protective effect against MTX toxicity (odds ratio: 0.37 [95% CI: 0.19-0.70]; p = 0.002). Results remained significant in multiple logistic regression analysis with the inclusion of disease and treatment features in the model (p = 0.03). Polymorphism 63/91 in gene promoter can modulate the onset of MTX-related adverse effects in RA patients.
ISSN:1462-2416
1744-8042
DOI:10.2217/pgs-2016-0090